-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nivolumab in Angiosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Angiosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in Angiosarcoma Drug Details: Nivolumab (Opdivo, Opdyta) is a human IgG4...
-
Product Insights
NewHypersomnia – Drugs In Development, 2024
Empower your strategies with our Hypersomnia – Drugs In Development, 2024 report and make more profitable business decisions. Hypersomnia is a neurological disorder of excessive time spent sleeping or excessive sleepiness. It can have many possible causes (such as seasonal affective disorder) and can cause distress and problems with functioning. It is a pathological state characterized by a lack of alertness during the waking episodes of the day. The main symptom of hypersomnia is excessive daytime sleepiness (EDS), or prolonged nighttime...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRG-2001 in Bone Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRG-2001 in Bone Disorders report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRG-2001 in Bone Disorders Drug Details: PRG-2001 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Atopic Dermatitis in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atopic Dermatitis in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Atopic Dermatitis in Atopic Dermatitis (Atopic Eczema)Drug Details: Small molecule...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bavisant Dihydrochloride in Hypersomnia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bavisant Dihydrochloride in Hypersomnia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Bavisant Dihydrochloride in Hypersomnia Drug Details:Bavisant dihydrochloride (BEN-2001, JNJ-31001074) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bremelanotide Acetate in Diabetic Nephropathy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bremelanotide Acetate in Diabetic Nephropathy Drug Details: Bremelanotide acetate (Vyleesi) is belongs to class of...
-
Company Insights
AstraZeneca Plc – Digital Transformation Strategies
Astrazeneca Digital Transformation Strategies Report Overview AstraZeneca uses AI-based technologies as a part of its digital transformation strategies. The annual ICT spending of AstraZeneca was estimated at $1 billion in 2023. A major share of this spending is earmarked for acquiring software, ICT services, and hardware from vendors. AstraZeneca Plc (AstraZeneca) is a biopharmaceutical company, which is focused on the discovery, production, and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory,...
-
Company Profile
BenevolentAI Ltd – Company Profile
BenevolentAI Ltd (BenevolentAI) is a drug discovery company. It carries out developing and applying artificial intelligence (AI) to produce new medicines for the treatment of diseases. The company’s drug programs include BEN2293 (atopic dermatitis), BEN8744 (ulcerative colitis), BEN9160 (amyotrophic lateral sclerosis), glioblastoma multiforme, inflammatory bowel disease, CNS diseases, antiviral, nonalcoholic steatohepatitis (NASH), oncology, Parkinson’s disease, chronic kidney disease, idiopathic pulmonary fibrosis and others. BenevolentAI’s platform enables scientists to design and develop new treatments for patients, using a large amount of...
Add to Basket -
Product Insights
Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glioblastoma Multiforme Pipeline Drugs Market Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness, and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy, and chemotherapy. The Glioblastoma Multiforme (GBM) drugs in development market research report provides comprehensive information on the therapeutics under...